Quality of life in childhood immune thrombocytopenia: international validation of the kids' ITP tools.

BACKGROUND: The Kids ITP Tools (KIT) is a disease-specific measure of health-related quality of life for children with immune thrombocytopenia (ITP). To facilitate use in international trials it has been cross-culturally adapted for France, Germany, the United Kingdom and Uruguay. This study assessed the validity and reliability of the translated KIT in comparison to generic quality of life measures. METHODS: Children 2-18 years of age with ITP and their parents were recruited in France, Germany, the United Kingdom and Uruguay. Participants completed the KIT, PedsQL and KINDL. We examined the Pearson's correlation between these measures for our pooled sample and estimated the reliability over a 2-week time period. Findings were further explored by country. RESULTS: A total of 127 families (81 children self-reported) participated. Mean child-reported scores were: KIT 74.3 (SD = 15.3), PedsQL 81.3 (SD = 13.0), and KINDL 70.5 (SD = 14.3). Corresponding mean parent proxy-reported scores were: 70.6 (SD = 18.1), 75.7 (SD = 16.8) and 72.3 (SD = 12.7), respectively. Correlation between KIT and the generic measures was consistent with our a priori hypothesis (PedsQL r = 0.54, KINDL r = 0.48, both P < 0.0001). Child KIT scores for newly diagnosed ITP patients were significantly lower than for chronic ITP patients (67.3 vs. 77.3; P = 0.005). There was a significant correlation (P < 0.001) between the child and parent proxy KIT scores (ICC = 0.52). Child KIT test-retest reliability was acceptable at 0.71. CONCLUSIONS: The cross-culturally translated KIT is valid and reliable with acceptable correlation to the PedsQL and KINDL. There is a significant difference in child self-reported KIT scores between newly diagnosed and chronic ITP.

Análisis del impacto de la pandemia COVID-19 sobre la calidad de los servicios de salud sexual y reproductiva / Impact of the COVID-19 pandemic on the quality of sexual and reproductive health services / Análise do impacto da pandemia COVID-19 sobre a qualidade dos serviços de saúde sexual e reprodutiva

Resumen: Antecedentes: la pandemia COVID-19 tiene el potencial de impactar fuertemente en la agenda de la salud y los derechos sexuales y reproductivos desde la disminución de la calidad de los servicios de salud. Justificación: Uruguay se destaca por una situación privilegiada en lo referido a los derechos sexuales y reproductivos y por tal motivo es necesario, por un lado, sistematizar el impacto de la pandemia COVID-19 y, por otro, desarrollar medidas para prevenir dicho impacto sobre los servicios para mantener el más alto estándar de cuidados en lo relacionado a los derechos sexuales y reproductivos a pesar de la pandemia actual. Propósito: sistematizar el potencial impacto de la pandemia en los servicios de atención sanitaria de salud sexual y reproductiva y promover estrategias para detectar y prevenir dicho impacto. Metodología: se aborda el impacto de la pandemia COVID-19 sobre los derechos sexuales y reproductivos en dos dimensiones: la del modelo de retrasos en la atención de salud y la del análisis del impacto en cada derecho específico. Perspectivas: promover acciones de discriminación positiva desde los servicios de salud sexual y reproductiva a la vez que se realiza la vigilancia epidemiológica para facilitar el acoplamiento de las prestaciones en derechos sexuales y reproductivos a los cambios que se procesan en la respuesta sanitaria y social frente a la pandemia COVID-19.

Summary: Background: the COVID 19 pandemic may severely influence the sexual and reproductive rights and health agenda as a result of a decrease in the health services. Justification: Uruguay has a privileged situation in terms of sexual and reproductive rights. Therefore, we need to systematize and develop measures to prevent the impact of the covid-19 pandemic on these services in order to keep the highest standards of care in connection with sexual and reproductive rights, despite the current pandemic. Objective: to systematize the potential impact of the covid-19 pandemic on sexual and reproductive rights and health services and to promote strategies to identify and prevent this impact. Method: the impact of the covid-19 pandemic on sexual and reproductive rights is analysed from two perspectives: by considering the delay in the provision of health care services and by exploring its impact on each specific sexual and reproductive right. Perspectives: to promote positive discrimination actions at the sexual and reproductive rights services, while conducting epidemiological surveillance to contribute to the matching of sexual and reproductive rights services to the changes caused by the covid-19 pandemic on the health system and on society.

Resumo: Antecedentes: a pandemia COVID-19 tem o potencial de impactar fortemente sobre a agenda da saúde e os direitos sexuais e reprodutivos a partir da queda na qualidade dos serviços de saúde. Justificativa: o Uruguai se destaca por uma situação privilegiada em matéria de direitos sexuais e reprodutivos (DDSSRR) e por isso é necessário, por um lado, sistematizar o impacto da pandemia COVID-19 e por outro, desenvolver medidas para prevenir esse impacto sobre os serviços para manter o mais alto padrão de atendimento em relação aos direitos sexuais e reprodutivos, apesar da pandemia atual. Objetivo: sistematizar o impacto potencial da pandemia COVID-19 nos serviços de saúde sexual e reprodutiva e promover estratégias para detectá-lo e preveni-lo. Metodologia: o impacto da pandemia COVID-19 sobre os DDSSRR é abordado em duas dimensões: a do modelo de atrasos na assistência de saúde e a da análise do impacto em cada um dos DDSSRR. Perspectivas: promover ações de discriminação positiva dos serviços de saúde sexual e reprodutiva, enquanto a vigilância epidemiológica é feita para facilitar o acoplamento dos benefícios dos direitos sexuais e reprodutivos às mudanças que ocorrem na resposta sanitária e social a pandemia COVID19.

Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience.

BACKGROUND: In 2006 the Hematology Service of Hospital Maciel published its experience with peripheral blood progenitor cell harvesting for autologous stem cell transplantation using Filgen JP (Clausen Filgrastim). After mobilization with a mean filgrastim dose of 78 mcg/Kg, 4.7 x 10(6) CD34(+) cells/Kg were obtained by apheresis. Age above 50, multiple myeloma as underlying disease and a malignancy that was not in remission were identified as frequent characteristics among patients showing complex mobilization. OBJECTIVE: The aim of this study was to compare stem cell mobilization using different brands of filgrastim. METHODS: One hundred and fifty-seven mobilizations performed between 1997 and 2006 were analyzed. This retrospective analysis comparative two groups of patients: those mobilized with different brands of filgrastim (Group A) and those who received Filgen JP (Clausen Filgrastim) as mobilizing agent (Group B). A cluster analysis technique was used to identify four clusters of individuals with different behaviors differentiated by age, total dose of filgrastim required, number of apheresis and harvested CD34(+) cells. RESULTS: The mean total dose of filgrastim administered was 105 mcg/Kg, the median number of apheresis was 2 procedures and the mean number of harvested stem cells was 4.98 x 10(6) CD34(+) cells/Kg. No significant differences were observed between Groups A and B regarding the number of apheresis, harvested CD34(+) cells and number of mobilization failures, however the total dose of filgrastim was significantly lower in Group B. CONCLUSIONS: Among other factors, the origin of the cytokine used as mobilizing agent is an element to be considered when evaluating CD34(+) cell mobilization results.

Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience

BACKGROUND:In 2006 the Hematology Service of Hospital Maciel published its experience with peripheral blood progenitor cell harvesting for autologous stem cell transplantation using Filgen JP (Clausen Filgrastim). After mobilization with a mean filgrastim dose of 78 mcg/Kg, 4.7 x 10(6) CD34(+) cells/Kg were obtained by apheresis. Age above 50, multiple myeloma as underlying disease and a malignancy that was not in remission were identified as frequent characteristics among patients showing complex mobilization.OBJECTIVE:The aim of this study was to compare stem cell mobilization using different brands of filgrastim.METHODS:One hundred and fifty-seven mobilizations performed between 1997 and 2006 were analyzed. This retrospective analysis comparative two groups of patients: those mobilized with different brands of filgrastim (Group A) and those who received Filgen JP (Clausen Filgrastim) as mobilizing agent (Group B). A cluster analysis technique was used to identify four clusters of individuals with different behaviors differentiated by age, total dose of filgrastim required, number of apheresis and harvested CD34(+) cells.RESULTS:The mean total dose of filgrastim administered was 105 mcg/Kg, the median number of apheresis was 2 procedures and the mean number of harvested stem cells was 4.98 x 10(6) CD34(+) cells/Kg. No significant differences were observed between Groups A and B regarding the number of apheresis, harvested CD34(+) cells and number of mobilization failures, however the total dose of filgrastim was significantly lower in Group B.CONCLUSIONS:Among other factors, the origin of the cytokine used as mobilizing agent is an element to be considered when evaluating CD34(+) cell mobilization results(AU)

Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience

BACKGROUND: In 2006 the Hematology Service of Hospital Maciel published its experience with peripheral blood progenitor cell harvesting for autologous stem cell transplantation using Filgen JP (Clausen Filgrastim). After mobilization with a mean filgrastim dose of 78 mcg/Kg, 4.7 x 10(6) CD34+ cells/Kg were obtained by apheresis. Age above 50, multiple myeloma as underlying disease and a malignancy that was not in remission were identified as frequent characteristics among patients showing complex mobilization. OBJECTIVE: The aim of this study was to compare stem cell mobilization using different brands of filgrastim. METHODS: One hundred and fifty-seven mobilizations performed between 1997 and 2006 were analyzed. This retrospective analysis comparative two groups of patients: those mobilized with different brands of filgrastim (Group A) and those who received Filgen JP (Clausen Filgrastim) as mobilizing agent (Group B). A cluster analysis technique was used to identify four clusters of individuals with different behaviors differentiated by age, total dose of filgrastim required, number of apheresis and harvested CD34+ cells. RESULTS: The mean total dose of filgrastim administered was 105 mcg/Kg, the median number of apheresis was 2 procedures and the mean number of harvested stem cells was 4.98 x 10(6) CD34+ cells/Kg. No significant differences were observed between Groups A and B regarding the number of apheresis, harvested CD34+ cells and number of mobilization failures, however the total dose of filgrastim was significantly lower in Group B. CONCLUSIONS: Among other factors, the origin of the cytokine used as mobilizing agent is an element to be considered when evaluating CD34+ cell mobilization results.

Estudio descriptivo retrospectivo del uso de Avirostat* (interferón alfa-2a) e INF* (interferón alfa-2b) y su tolerancia en tumores sólidos. Experiencia del Instituto Nacional del Cáncer. (Montevideo, Uruguay)

Los interferones alfa, tanto 2a como 2b, representan hoy en día una de las principales alternativas terapéuticas para ciertas patologías oncológicas, tanto con criterio terapéutico como adyuvante. En el siguiente estudio se analizaron las historias clínicas de 24 pacientes portadores de melanoma maligno o carcinoma renal, tratados con AVIROSTAT (interferón alfa-2a Clausen) o con INF (interferón alfa-2b Clausen), entre enero de 2002 y marzo de 2006. La dosis utilizada fue de 3 MUI tres veces por semana, por vía subcutánea. A la dosis indicada los interferones alfa-2a y 2b fueron bien tolerados desde el punto de vista local y sistémico, destacándose que los síntomas y signos disminuyeron a medida que transcurrió el tratamiento. No fue necesaria la suspensión del tratamiento debido a los eventos adversos. Con respecto a la sobrevida, debido a la naturaleza retrospectiva del estudio no pudo obtenerse un resultado concluyente

Evaluación de Eritrogen (Eritropoyetina Alfa Clausen - Eritropoyetina Iclos) en el tratamiento de la anemia en pacientes con insuficiencias renal crónica en dialisis. Uruguay 2006 / Eritrogen assessment (Clausen Alfa Erythropoietin - Erythropoietin Iclos) in the treatment of anemia in chronic renal failure patients on dialysis. Uruguay 2006

El uso clínico de eritropoyetina ha permitido mejorar el tratamiento de la ñanemia en los pacientes con insuficiencia renal crónica en diálisis. El presente estudio describe la experiencia de los centros de diálisis de Paysandú, Rocha, Canelones, Treinta y Tres y Lavalleja, a partir de enero de 2004, con el uso de ERITROGEN en 82 pacientes. Treinta y ocho pacientes comenzaron su tratamiento con ERITROGEN y otros 44 estaban recibiendo otra marca comercial de eritropoyetina antes de comenzar a recibir ERITROGEN. La vía de administración elegido fue la subcutánea. Se evaluó la respuesta tanto en términos de recuperación de la anemia, como en términos de tolerancia al tratamiento con ERITROGEN. La dosis promedio al sexto mes de tratamiento de de 5.000 UI por semana, siendo los valores de hematocrito y hemoglobina alacanzados ampliamente satisfactorios. Además, ningún paicente debió suspender el tratamiento debido a efectos adeversos(AU)